Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED.

OI FEB 15 PM 3-14

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Registrant Nature McGuiness & Holch]			
2. Address Li Check if different than previously reported	ļ			
400 N Capitol St., NW, Suite 585 J. Principal Place of Business (if different from line 2)	, Washi	ngton DC 20001		
City:		·		
4. Contact Name Telephone	(Zip {or Country)	E-mail (optional)	5. Senate ID#	
Markham Erickson (202) 783-5300) Markh		2446436	
7. Client Name D Self		.	6. House ID #	
Barr Labs	,		31534000	
0. Check if this is a Termination Report □ ⇒ Termination INCOME OR EXPENSES - Complete Either	Line 12 O	R Line 13	1. No Lobbying Activity C	
12. Lobbying Firms		13. Organiza	tions	
INCOME relating to loobying activities for this reporting period was:	EXPENSE period were	S relating to lobbying activ		
Less than \$10,000 · 🗔	Less thon \$	10,000 🔲		
\$10,000 or more	\$10,000 or more			
\$10,000 or more \$\frac{1}{\times} \frac{5}{4.0,000} \text{heome (nearest \$20,000)} \	14. REPO	Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.		
	accounting			
	Method A. Reporting amounts using LDA definitions only			
	Method B. Reporting amounts under section 6033(b)(8)of the Internal Revenue Code			
	☐ Method	C. Reporting amounts un Internal Revenue Cod	ider section 162(e) of the	
ignature)			
risted Name and Title	.,			
D-2 (REV. 6/98)			PAGET OF 3	

Registrant Name McGuiness & Holch Client 1	Name Batt	
LOBBYING ACTIVITY. Select as many codes as necessengaged in lobbying on behalf of the client during the repoinformation as requested. Attach additional page(s) as nee	orting period. Using a separate page for each code, provi eded.	ant ide
15. General issue area code PHA (one pur page)		
16. Specific lobbying issues		
Issues relating to FDA drug approximatket exclusivity of drugs.	proval time; issues relating to	
17. House(s) of Congress and Federal agencies contacted	Check if None	
Senate House of F	Reps.	
•		
18. Name of each individual who acted as a lobbyist in this	is issue area	
Name	Covered Official Position (if applicable)	New
Kevin McGuiness		a
	THE RESIDENCE OF THE PROPERTY	٥
	ĺ	٥
	<u> </u>	O.
		<u> </u>
		1]
	The state of the s	O
19. Interest of each foreign entity in the specific issues listed on 1	line 16 above Check if None	
Signature	Date	
Printed Name and Title		
Yami 4.D-2 (Rev.to/IS)	Page 2 or 3	3
	l'age til	
	:	

Name Barr
sary to reflect the general issue areas in which the registrant orting period. Using a separate page for each code, provide ided.
ucu.
l time; isues relating to
Check if None
s issue area
Covered Official Position (if applicable) New
Q
G
O
į a
ine 16 above
Date 2-14-01
Atturney